In last trading session, Soleno Therapeutics Inc (NASDAQ:SLNO) saw 0.78 million shares changing hands with its beta currently measuring -2.65. Company’s recent per share price level of $73.26 trading at -$0.97 or -1.31% at ring of the bell on the day assigns it a market valuation of $3.66B. That closing price of SLNO’s stock is at a discount of -1.69% from its 52-week high price of $74.50 and is indicating a premium of 49.59% from its 52-week low price of $36.93. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.02 million shares which gives us an average trading volume of 1.21 million if we extend that period to 3-months.
For Soleno Therapeutics Inc (SLNO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.11. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
Soleno Therapeutics Inc (NASDAQ:SLNO) trade information
Upright in the red during last session for losing -1.31%, in the last five days SLNO remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $73.26 price level, adding 1.66% to its value on the day. Soleno Therapeutics Inc’s shares saw a change of 62.98% in year-to-date performance and have moved 4.69% in past 5-day. Soleno Therapeutics Inc (NASDAQ:SLNO) showed a performance of 49.60% in past 30-days. Number of shares sold short was 4.66 million shares which calculate 2.52 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 91.5 to the stock, which implies a rise of 19.93% to its current value. Analysts have been projecting 70 as a low price target for the stock while placing it at a high target of 105. It follows that stock’s current price would jump 4.45% in reaching the projected high whereas dropping to the targeted low would mean a gain of 4.45% for stock’s current value.
And 8 analysts are in estimates of company making revenue of 3.09M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 20.19% during past 5 years.
Soleno Therapeutics Inc (NASDAQ:SLNO)’s Major holders
Insiders are in possession of 2.40% of company’s total shares while institution are holding 103.22 percent of that, with stock having share float percentage of 105.76%. Investors also watch the number of corporate investors in a company very closely, which is 103.22% institutions for Soleno Therapeutics Inc that are currently holding shares of the company. VIVO CAPITAL, LLC is the top institutional holder at SLNO for having 7.32 million shares of worth $298.53 million. And as of 2024-06-30, it was holding 18.9401 of the company’s outstanding shares.
The second largest institutional holder is CARLYLE GROUP INC., which was holding about 4.07 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.5395 of outstanding shares, having a total worth of $166.36 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.13 shares of worth $82.67 million or 2.26% of the total outstanding shares. The later fund manager was in possession of 933.3 shares on Dec 31, 2024 , making its stake of worth around $68.37 million in the company or a holder of 1.87% of company’s stock.
